Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08VKZ
|
||||
| Former ID |
DIB001516
|
||||
| Drug Name |
Edaglitazone
|
||||
| Synonyms |
Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Terminated | [526596] | ||
| Company |
Roche Holding AG
|
||||
| Canonical SMILES |
N1C(=O)SC(C1=O)Cc1c2c(c(cc1)OCCc1nc(oc1C)c1ccccc1)ccs2
|
||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Modulator | [526596] | |
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.